Drug intelligence / Profile preview

CADI-05 + cisplatin + paclitaxel

Development stage: Unknown
Lead developer: Cadila Pharmaceuticals
Modality: Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous, Intravesical

Overview

CADI-05 + cisplatin + paclitaxel is a combination therapy that has been studied primarily for the treatment of advanced non-small cell lung cancer (NSCLC). This combination represents a chemoimmunotherapy approach, combining traditional chemotherapy agents (cisplatin and paclitaxel) with an immunomodulator (CADI-05).

Other names: Mycobacterium indicus praniiMycobacterium w

Targets

TUBB (Tubulin (alpha and beta subunits))TLR2 (Toll-like Receptor 2)DSC3 (Desmocollin-3)DNA

Beyond the preview

Go deeper on CADI-05 + cisplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CADI-05 + cisplatin + paclitaxel.

Explore the full profile